Generation of monoclonal antibody producing human hybridomas: Optimized conditions

B. Switzer, I. Blanco, M. Singhai, D. Colcher, D. R. Johnson

Research output: Contribution to journalArticle

Abstract

Human monoclonal antibodies (Mabs) can be created from peripheral blood lymphocytes (PBL) by EBV-transformation (EBV-t) or by direct fusion to human or mouse myeloma lines. EBV-t cell lines are difficult to clone and have low levels of antibody production. As an alternative, we evaluated the development of human Mab producing hybridomas from EBV-t and mitogen stimulated PBL. EBV-t or pokeweed mitogen stimulated (PWM-s) PBL from immunized patients enrolled in a vaccine trial were fused using polyethylene glycol (PEG) at a 1:1 ratio with K6H6/B5 cells. The cells were then plated at 5xl04 per well in RPMI-1640 media (+15% FBS+ 1% ORIGEN HCF (IGEN)), followed by HAT/ouabain selection. High fusion growth rates (avg. 317 wells/107 PBL) were observed. PWM-s hybrids initially produced a more diverse distribution of immunoglobulin classes (IgG and IgM) than EBV-t hybrids EBV-t hybrids maintained antibody production during serial cloning for 120 days. After the last cloning, Mab levels decreased gradually over a period of 60 days, from 7.0-29.0 ug/ml/106 cells to 2.7-16.0 ug/ml/IO6 cells, without losing antigen specificity. We successfully produced and maintained human Mabs with either stimulation method.

Original languageEnglish (US)
Pages (from-to)A1058
JournalFASEB Journal
Volume10
Issue number6
StatePublished - Dec 1 1996

Fingerprint

hybridomas
Lymphocytes
Hybridomas
Human Herpesvirus 4
monoclonal antibodies
Blood
lymphocytes
Monoclonal Antibodies
Pokeweed Mitogens
Phytolacca americana
Cloning
blood
antibody formation
molecular cloning
Fusion reactions
cells
myeloma
ouabain
Antibody Formation
human development

ASJC Scopus subject areas

  • Biotechnology
  • Biochemistry
  • Molecular Biology
  • Genetics

Cite this

Switzer, B., Blanco, I., Singhai, M., Colcher, D., & Johnson, D. R. (1996). Generation of monoclonal antibody producing human hybridomas: Optimized conditions. FASEB Journal, 10(6), A1058.

Generation of monoclonal antibody producing human hybridomas : Optimized conditions. / Switzer, B.; Blanco, I.; Singhai, M.; Colcher, D.; Johnson, D. R.

In: FASEB Journal, Vol. 10, No. 6, 01.12.1996, p. A1058.

Research output: Contribution to journalArticle

Switzer, B, Blanco, I, Singhai, M, Colcher, D & Johnson, DR 1996, 'Generation of monoclonal antibody producing human hybridomas: Optimized conditions', FASEB Journal, vol. 10, no. 6, pp. A1058.
Switzer B, Blanco I, Singhai M, Colcher D, Johnson DR. Generation of monoclonal antibody producing human hybridomas: Optimized conditions. FASEB Journal. 1996 Dec 1;10(6):A1058.
Switzer, B. ; Blanco, I. ; Singhai, M. ; Colcher, D. ; Johnson, D. R. / Generation of monoclonal antibody producing human hybridomas : Optimized conditions. In: FASEB Journal. 1996 ; Vol. 10, No. 6. pp. A1058.
@article{f1c3e6d2a88e42c3926a19de9a5fe034,
title = "Generation of monoclonal antibody producing human hybridomas: Optimized conditions",
abstract = "Human monoclonal antibodies (Mabs) can be created from peripheral blood lymphocytes (PBL) by EBV-transformation (EBV-t) or by direct fusion to human or mouse myeloma lines. EBV-t cell lines are difficult to clone and have low levels of antibody production. As an alternative, we evaluated the development of human Mab producing hybridomas from EBV-t and mitogen stimulated PBL. EBV-t or pokeweed mitogen stimulated (PWM-s) PBL from immunized patients enrolled in a vaccine trial were fused using polyethylene glycol (PEG) at a 1:1 ratio with K6H6/B5 cells. The cells were then plated at 5xl04 per well in RPMI-1640 media (+15{\%} FBS+ 1{\%} ORIGEN HCF (IGEN)), followed by HAT/ouabain selection. High fusion growth rates (avg. 317 wells/107 PBL) were observed. PWM-s hybrids initially produced a more diverse distribution of immunoglobulin classes (IgG and IgM) than EBV-t hybrids EBV-t hybrids maintained antibody production during serial cloning for 120 days. After the last cloning, Mab levels decreased gradually over a period of 60 days, from 7.0-29.0 ug/ml/106 cells to 2.7-16.0 ug/ml/IO6 cells, without losing antigen specificity. We successfully produced and maintained human Mabs with either stimulation method.",
author = "B. Switzer and I. Blanco and M. Singhai and D. Colcher and Johnson, {D. R.}",
year = "1996",
month = "12",
day = "1",
language = "English (US)",
volume = "10",
pages = "A1058",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "6",

}

TY - JOUR

T1 - Generation of monoclonal antibody producing human hybridomas

T2 - Optimized conditions

AU - Switzer, B.

AU - Blanco, I.

AU - Singhai, M.

AU - Colcher, D.

AU - Johnson, D. R.

PY - 1996/12/1

Y1 - 1996/12/1

N2 - Human monoclonal antibodies (Mabs) can be created from peripheral blood lymphocytes (PBL) by EBV-transformation (EBV-t) or by direct fusion to human or mouse myeloma lines. EBV-t cell lines are difficult to clone and have low levels of antibody production. As an alternative, we evaluated the development of human Mab producing hybridomas from EBV-t and mitogen stimulated PBL. EBV-t or pokeweed mitogen stimulated (PWM-s) PBL from immunized patients enrolled in a vaccine trial were fused using polyethylene glycol (PEG) at a 1:1 ratio with K6H6/B5 cells. The cells were then plated at 5xl04 per well in RPMI-1640 media (+15% FBS+ 1% ORIGEN HCF (IGEN)), followed by HAT/ouabain selection. High fusion growth rates (avg. 317 wells/107 PBL) were observed. PWM-s hybrids initially produced a more diverse distribution of immunoglobulin classes (IgG and IgM) than EBV-t hybrids EBV-t hybrids maintained antibody production during serial cloning for 120 days. After the last cloning, Mab levels decreased gradually over a period of 60 days, from 7.0-29.0 ug/ml/106 cells to 2.7-16.0 ug/ml/IO6 cells, without losing antigen specificity. We successfully produced and maintained human Mabs with either stimulation method.

AB - Human monoclonal antibodies (Mabs) can be created from peripheral blood lymphocytes (PBL) by EBV-transformation (EBV-t) or by direct fusion to human or mouse myeloma lines. EBV-t cell lines are difficult to clone and have low levels of antibody production. As an alternative, we evaluated the development of human Mab producing hybridomas from EBV-t and mitogen stimulated PBL. EBV-t or pokeweed mitogen stimulated (PWM-s) PBL from immunized patients enrolled in a vaccine trial were fused using polyethylene glycol (PEG) at a 1:1 ratio with K6H6/B5 cells. The cells were then plated at 5xl04 per well in RPMI-1640 media (+15% FBS+ 1% ORIGEN HCF (IGEN)), followed by HAT/ouabain selection. High fusion growth rates (avg. 317 wells/107 PBL) were observed. PWM-s hybrids initially produced a more diverse distribution of immunoglobulin classes (IgG and IgM) than EBV-t hybrids EBV-t hybrids maintained antibody production during serial cloning for 120 days. After the last cloning, Mab levels decreased gradually over a period of 60 days, from 7.0-29.0 ug/ml/106 cells to 2.7-16.0 ug/ml/IO6 cells, without losing antigen specificity. We successfully produced and maintained human Mabs with either stimulation method.

UR - http://www.scopus.com/inward/record.url?scp=33748912884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748912884&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748912884

VL - 10

SP - A1058

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 6

ER -